Mounjaro (tirzepatide) is a once-weekly injectable prescription medication approved by the FDA in May 2022 for adults with type 2 diabetes to improve blood sugar control alongside diet and exercise. The same molecule
Sources
- FDA label: Mounjaro (tirzepatide) injection, Eli Lilly and Company, revised 2024
- SURPASS-1 trial: Frías JP et al., N Engl J Med, 2021
- SURPASS-2 trial: Frías JP et al., N Engl J Med, 2021
- SURPASS-CVOT trial: Eli Lilly, NCT04255433
- SURMOUNT-1 trial: Jastreboff AM et al., N Engl J Med, 2022
- FDA approval of Zepbound (tirzepatide) for obesity, November 2023
- FDA Prescribing Information: Mounjaro, Reference ID 5219786
- Eli Lilly Mounjaro Savings Card program terms, 2026